NCT07740603

Brief Summary

Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow. The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
11mo left

Started Jul 2026

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Jul 2026Jul 2027

Study Start

First participant enrolled

July 1, 2026

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

July 25, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 31, 2026

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

July 31, 2026

Status Verified

July 1, 2026

Enrollment Period

11 months

First QC Date

July 25, 2026

Last Update Submit

July 29, 2026

Conditions

Chronic Myeloid Leukemia (CML)

Outcome Measures

Primary Outcomes (1)

  • an increased change in cd 38 and cd 56 in chronic leukemic patients

    6 months

Study Arms (2)

chronic myeloid leukemia group

Diagnostic Test: cd 38 and cd 56

healthy group

Interventions

cd 38 and cd 56DIAGNOSTIC_TEST

prescence of high percentage of cd38 and cd 56

chronic myeloid leukemia group

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients in sohag city

You may qualify if:

  • patients with chronic myeloid leukemia

You may not qualify if:

  • other hematological diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsMyeloproliferative DisordersBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Menna Mostafa Zaki

CONTACT

01152386116mennazaki133@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident

Study Record Dates

First Submitted

July 25, 2026

First Posted

July 31, 2026

Study Start

July 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

July 31, 2026

Record last verified: 2026-07